Jill Wechsler

Jill Wechsler is Pharmaceutical Technology's Washington editor. She can be contacted by postal mail at 7715 Rocton Ave., Chevy Chase, MD 20815, by telephone at 301.656.4634, or by e-mail at jillw2@olg.com.

More information may be released to improve public understanding of regulatory policies.

FDA and industry seek to ensure drug quality and safety in a world complicated by global outsourcing and rising theft.

Manufacturers will pay new fees but anticipate expanded drug use and safeguards for innovation.

FDA lacks resources to manage expanding postmarketing responsibilities.

After months of increasingly rancorous debate, the House finally approved legislation on Mar. 21, 2010, that makes significant changes in the nation's healthcare system.

FDA modernizes information systems, expands access to drug safety and use information.

Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.

Globalization and reform initiatves will shape pharma production, pricing, and pipelines in 2010.

Generic-drug manufacturers look to expand into biologics and complex dosage forms. This article contains bonus online-exclusive material.